2023年6月23日

她最近擔任全球首席科學官,首席醫療官Veracyte。總經理邁克爾Barbella Editor06.23.23 Acuamark診斷已任命會肯尼迪博士,其董事會。“我尊敬,會選擇支持AcuamarkDx的任務和工作的最新成員我們的董事會,“AcuamarkDx聯合創始人/首席執行官伯納德Peperstraete博士說。“敏銳的才智,深深入人性和幾十年的基因診斷發展,公司大樓,和商業化的經驗,她帶來了一個令人耳目一新的視角Acuamark當我們進入一個新階段的發展。“肯尼迪博士是一位多產的研究、產品和臨床發展執行官擁有超過20年的經驗推動新型診斷技術從早期階段研究到商業化和采用。她最近擔任全球首席科學官,首席醫療官Veracyte,癌症遺傳學公司專注於各種癌症的治療計劃和預測。那裏,她管理一個全球團隊的研發、醫療事務,數據科學和臨床事務專家燃料研究和開發公司的基因組和其他診斷測試。她一直參與Veracyte的發展和增長自成立以來。加入Veracyte之前,Affymetrix肯尼迪博士,加速公司的商業化平台為多個新興市場。“Acuamark是專有的,高通量qPCR技術旨在提供早期癌症的高度敏感和非常具體的結果在規模,解決的經典的權衡blood-based診斷學的發展。與任務順序疾病的預測癌症檢測和細心的監視程序的一部分初級保健模型為無症狀的人群,Acuamark潛力真正健康保健的重點轉移到預防,”肯尼迪博士說。 "I’m very pleased to join the Acuamark Board of Directors and to bring my expertise in company building and in development and commercialization of diagnostics products to bear on further advancing the company.” “Dr. Kennedy is a life science business leader who has headed research and development operations from a company’s inception to IPO and beyond,” Acuamark Executive Board Chairman William Gedale said. “Her diverse experience in the diagnostic industry, as well as her expertise in attracting capital and driving commercial development, are essential to this phase of Acuamark’s growth. We’re very glad to welcome her to the board.” Acuamark Diagnostics, Inc. is a molecular diagnostics company developing an ultra-sensitive, automatable technology designed for more reliable and cost-effective early-cancer detection. The blood-based assays are intended to solve for the classic diagnostic tradeoff, providing both highly sensitive and highly specific results at scale that can make frequent, recurrent sequential cancer monitoring the standard of primary care. With this accurate early-stage cancer detection, Acuamark aims to shift treatment to earlier stages of disease to improve patient outcomes, reduce economic burden of care and advance a more equitable model of care. Trending